Table 1 Clinical and demographic features of the studied subjects
Characteristics | SLE patients | Healthy controls | |
|---|---|---|---|
Pre-treatment | Post-treatment | ||
No. of cases | 40 | 40 | 40 |
Female, n (%) | 36 (90.0%) | 36 (90.0%) | 36 (90.0%) |
Male, n (%) | 4 (10%) | 4 (10%) | 4 (10%) |
Age, years (range) | 33.7 (20 ~ 55) | 33.7 (20 ~ 55) | 34.8 (21 ~ 57) |
Course of disease months | 11.2 (1 ~ 26) | 12.2 (2 ~ 27) | - |
(range) | |||
SLEDAI (mean ± SD) | 11.45 ± 3.76 | 7.90 ± 4.00 | - |
Skin and mucosa lesion | 28 (70.0%) | 15 (37.5%0) | - |
Serositis, n (%) | 15 (37.5%) | 8 (20.0%) | - |
Arthritis, n (%) | 18 (45.0%) | 4 (10.0%) | - |
Lupus nephritis, n (%) | 24 (60.0%) | 20 (50%) | - |
Hematologic involvement | 25 (62.5%) | 9 (22.5%) | - |
NPSLE, n (%) | 1 (2.5%) | 0 | - |
ANA, n (%) | 40 (100%) | 39 (97.5%) | 0 |
Anti-dsDNA antibody, (%) | 18 (45.0%) | 14 (35.0%) | 0 |